GlassScriptPhysician profile
Anthony G Maniscalco
NPI 1659371144
$6,375.71
in general payments reported to CMS, 2019-2025
50 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $715 · 2021: $984 · 2022: $785 · 2023: $894 · 2024: $1,325 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984 · Education: $17.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.79 |
| Education | $17.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $534.90 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $487.86 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $482.56 | 2021-2025 | Nuplazid |
| Amgen INC. | $435.35 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $357.73 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Emd Serono, INC. | $354.56 | 2019-2024 | Mavenclad, Mavenclad |
| Neurocrine Biosciences, INC. | $299.84 | 2020-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $278.30 | 2019-2025 | |
| Biogen, INC. | $275.40 | 2019-2024 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $261.65 | 2020-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $182.94 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $163.63 | 2023-2024 | Rytary, Crexont, Ongentys |
| Lundbeck LLC | $148.04 | 2019-2025 | Vyepti, Rexulti |
| Avanir Pharmaceuticals, INC. | $143.95 | 2019-2022 | |
| Genentech USA, INC. | $141.35 | 2019-2025 | Ocrevus Zunovo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Maniscalco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.